bacterial lipid A precursors

structure given in first source; lipid A precursor has been fractionated into eight related anionic components: lipid IA, IB, IIA, IIB, IIIA, IIIB, IVA, IVB; see also specific lipid A precursors, lipid X and lipid Y from E coli

Also Known As:

lipid A precursors, bacterial; compound 406; lipid A precursor IA; lipid A precursor, Salmonella typhimurium; lipid A precursors, Pseudomonas; lipid A precursors, Salmonella; lipid IVA; tetraacyl disaccharide 1,4'-bisphosphate

Networked: 9 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Chen, Yi: 1 article (11/2021)
2.	Hu, Yebei: 1 article (11/2021)
3.	Lu, Haojie: 1 article (11/2021)
4.	Luo, Haixin: 1 article (11/2021)
5.	Song, Xiuzu: 1 article (11/2021)
6.	Xie, Bo: 1 article (11/2021)
7.	Xu, Jinhui: 1 article (11/2021)
8.	Gu, Lan: 1 article (01/2019)
9.	Han, Jiahuai: 1 article (01/2019)
10.	Lu, Ben: 1 article (01/2019)

Related Diseases

1.	Necrosis 01/01/1989 - "Compound 406 and 506 elicited bone marrow reactions in mice and hemagglutination of mouse RBC, although 406 failed to elicit hemorrhage and necrosis also in mice skin. " 09/01/2003 - "Compound 411, the non-reducing sugar moiety of compound 506, exhibited interleukin-8 (IL-8) and tumour necrosis factor-alpha (TNF-alpha)-producing activities in human peripheral blood mononuclear cells (PBMC), whereas compound 401, the reducing moiety of compounds 506 and 406, and Gifu lipid A-46 (GLA-46), the non-reducing moiety of compound 406, induced no production of IL-8 and TNF-alpha, which was similar to the findings for compound 406. "
2.	Inflammation (Inflammations) 01/01/2023 - "A higher abundance of Prevotella timonensis at baseline was significantly associated with long-term cure failure of BV and greatly contributed to the enrichment of the lipid IVA synthesis pathway, which could aggravate inflammation response. " 04/01/1990 - "NAP-1/IL-8 promoted additional adhesive interactions between CD11b/CD18 and the biosynthetic precursor of LPS, lipid IVa, fibrinogen, and endothelial cells, suggesting that NAP-1/IL-8 may promote leukocyte adhesion in vivo that could lead to recruitment of PMN to sites of tissue inflammation."
3.	Sepsis (Septicemia) 10/15/1991 - "RSLA and lipid IVA may be useful in defining the role of LPS in Gram-negative bacterial infections and may prove to be prototypical therapeutic agents for the treatment of Gram-negative septicemia."
4.	Gram-Negative Bacterial Infections 10/15/1991 - "RSLA and lipid IVA may be useful in defining the role of LPS in Gram-negative bacterial infections and may prove to be prototypical therapeutic agents for the treatment of Gram-negative septicemia."
5.	Whooping Cough (Pertussis) 05/22/2015 - "pertussis LPS, and their mutation does not affect the response to hexa-acylated Escherichia coli LPS or tetra-acylated lipid IVA. "

Related Drugs and Biologics

1.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
2.	Lipids
3.	HMGB1 Protein (HMG1)
4.	Complementary DNA (cDNA)
5.	Arachidonic Acid (Vitamin F)
6.	Interleukin-8 (Interleukin 8)
7.	Lipid A
8.	Fibrinogen (Factor I)
9.	Acids
10.	Sugars